Recognition and Response: Two Different Presentations

Cannabis overconsumption: what it looks like human data

Acute overconsumption of cannabis, most commonly from an edible, presents as a cluster of unpleasant but generally self-limiting findings: tachycardia, anxiety that can reach frank panic with a sense of impending death, orthostatic hypotension and dizziness on standing, conjunctival injection, nausea and vomiting, impaired coordination, and in some people transient psychotic features including paranoia and, less often, hallucinations. It is frightening out of proportion to its danger, and the frightening quality is part of the clinical problem because panic amplifies the tachycardia and the sense of catastrophe. It is very rarely lethal by itself in an otherwise healthy adult, and the usual course is resolution over hours as the drug is cleared — slowly, if it was ingested, which is why the experience can last much longer than people expect. The two situations that change that assessment are a person with significant cardiac disease, in whom the tachycardia and blood-pressure changes are not trivial, and a child, for whom an adult edible dose is a genuine emergency and has produced severe central nervous system depression requiring admission. Separately, heavy chronic use is associated with cannabinoid hyperemesis syndrome: recurrent episodes of intractable vomiting and abdominal pain, classically relieved temporarily by hot showers or baths, resolving with cessation and recurring on resumption. It is documented, frequently misdiagnosed for years, and can produce dehydration and electrolyte disturbance serious enough to require treatment even though its mechanism is not acute toxicity.

Sources: Monte AA 2019 · Allen JH 2004 · Huestis MA 2007 · Lucas CJ 2018

Synthetic full-agonist toxicity: what is added, and why it is different human data

Synthetic cannabinoid receptor agonist toxicity includes some of the same features and then adds a set that cannabis does not produce, because a full agonist with no ceiling can drive receptor signalling — and downstream sympathetic and central effects — past where a partial agonist stops. The added features documented across clinical case series and systematic review are agitated delirium and violent agitation, sometimes requiring physical and chemical restraint; seizures, including generalised tonic-clonic seizures and status epilepticus; marked hypertension, and in other patients profound hypotension; tachyarrhythmias, with myocardial ischaemia and frank infarction reported in adolescents and young adults without coronary disease; hyperthermia; rhabdomyolysis, with acute kidney injury reported in clusters; profound central nervous system depression at the other end of the spectrum, as in the Brooklyn presentation; and death. The practical statement that follows is the one that matters most on this page: this does not respond the same way. Reassurance, a quiet low-stimulus room, fluids and time — which is usually the correct and sufficient management of cannabis overconsumption — is not sufficient here, because the trajectory is not self-limiting in the same way and the complications are the kind that require monitoring, active intervention and laboratory investigation. Treating a suspected synthetic-cannabinoid presentation as a bad weed trip, in the belief that waiting it out is the kind thing to do, is how a survivable event becomes a fatal one.

Sources: Hermanns-Clausen M 2013 · Tait RJ 2015 · Castaneto MS 2014 · Adams AJ 2017 · Thornton SL 2013 · Mir A 2011 · Trecki J 2015

When it is an emergency human data

The thresholds below are the documented ones, and they are deliberately low, because the cost of an unnecessary emergency assessment is small and the cost of a missed one is not recoverable. Call emergency services for a seizure of any duration, and immediately for a second seizure or one that does not stop. Call for chest pain, for collapse, for loss of consciousness or any state in which the person cannot be roused to purposeful response. Call for a high body temperature, for agitation that cannot be safely managed, and for any breathing difficulty. Call if the person is a child who has ingested a cannabis product, whatever they look like at the time, because the onset is delayed and the trajectory in a small body is not the adult one. And call, or at minimum call poison control, whenever the substance involved may be an unidentified or novel compound — because in that case nobody, including a clinician, can predict the course from the first hour, and the value of early assessment is highest precisely where the pharmacology is unknown. One more threshold that is easy to miss: a presentation that is out of proportion to what was supposedly taken is itself a warning sign, since it means either the dose or the identity of the substance is not what was believed, which is the signature of a hot spot or a mislabelled product.

• Seizure — any. Chest pain. Collapse or unrousable unresponsiveness. Difficulty breathing.
• High temperature. Agitation that cannot be safely managed.
• A child who has ingested a cannabis product — always, regardless of how they look initially.
• Any suspicion of an unidentified or novel compound.
• A presentation out of proportion to the reported dose — the dose or the identity is wrong.

Sources: Tait RJ 2015 · Castaneto MS 2014 · Monte AA 2019 · Burgess A 2024

Naloxone: the honest answer human data

Naloxone does not reverse cannabinoid toxicity. It is a competitive antagonist at opioid receptors and has no action at cannabinoid receptors, so it will not touch the agitation, the seizures, the tachyarrhythmia or the sedation of a synthetic cannabinoid receptor agonist. Anyone who says otherwise is wrong, and expecting it to work is dangerous because it substitutes for calling for help. And the second half of the answer matters just as much: giving naloxone is still frequently the right first action when opioids cannot be excluded. Polysubstance use is the norm rather than the exception, the illicit supply is contaminated with fentanyl and its analogues across much of North America, products of unknown composition are by definition of unknown composition, and an unresponsive person with depressed breathing may be having an opioid event regardless of what they or their friends believe they took. Naloxone given to someone who has not taken opioids does essentially nothing; naloxone withheld from someone who has can cost them their life. So the correct framing to carry is both clauses at once: naloxone will not fix cannabinoid toxicity, and it may still be the right first action if opioids are possible. In an unresponsive person with slow or absent breathing, give it, call emergency services, and manage the airway — do not stand and reason about which drug it was.

• No opioid receptor involvement — naloxone does not reverse cannabinoid toxicity.
• Give it anyway if opioids cannot be excluded: unresponsive plus depressed breathing is an opioid-possible event.
• It is close to harmless in a person who has not taken opioids.
• Naloxone is never a substitute for calling emergency services.

Sources: Castaneto MS 2014 · Tait RJ 2015 · Trecki J 2015

Poison control: what it is, and what it is not human data

In the United States the Poison Help line is 1-800-222-1222. It routes to a regional poison centre staffed around the clock by nurses, pharmacists and physicians with toxicology training, the call is free, and it is confidential. It is not law enforcement. Calling poison control is not calling the police, poison centres do not dispatch police, and their function is clinical advice — including advice that resolves the situation at home without an emergency department visit, which is the outcome in a large share of calls. The belief that calling will bring the police is widespread and it kills people, because it converts a phone call into a delay measured in hours. Say what to tell them, so the call is efficient: the product as it was labelled or described, anything known about the actual compound, how much, by what route, how long ago, the person's approximate age and weight, what they are doing right now, and anything else they have taken including alcohol and prescribed medication. If there is packaging, remaining material, or a photograph of a label, have it in hand — and keep it, because it is the only route to identification after the fact, both for the clinicians treating this person and for the surveillance system that might warn the next one. Outside the United States the equivalent national poison information service is the thing to look up before it is needed rather than during.

Sources: America's Poison Centers (formerly the American Association of Poison Control Centers) 2025* · Law RK 2016 · Burgess A 2024

Harm-reduction basics that change outcomes human data

The measures below are the ones with the clearest link to outcome, and none of them requires anyone to have made a different decision about whether to use. Do not use alone. An unresponsive person who is alone has no one to place them in the recovery position, no one to call, and no one to tell the clinicians what happened; almost every fatal outcome in this literature has that structure. Stagger use in a group rather than everyone dosing simultaneously from the same material, so that someone is in a position to help — this is exactly the defence against a hot spot, where the material that one person tolerated may not be what the next person gets. Start low and wait past the expected peak for the route, which is minutes to tens of minutes for inhalation and hours for ingestion; the titration page has the numbers. Use a known source and a product with a batch-matched certificate, and keep the packaging. If someone becomes unwell, tell the clinicians honestly and completely what was taken, including the things that are awkward to admit: they cannot treat what they do not know about, routine drug screens will not detect synthetic cannabinoid receptor agonists, and an incomplete history is the single most common reason a treatable presentation is managed wrongly. If a person is unresponsive but breathing, place them on their side in the recovery position with the head tilted to keep the airway clear and stay with them; if breathing is absent or agonal, that is a resuscitation situation and emergency services need to be on the line. None of this is instruction in the care of a specific person, and none of it replaces a clinician — it is the documented list of the things that make the difference between an event someone walks away from and one they do not.

• Do not use alone. Stagger use in a group so someone can act.
• Start low; wait past the peak for the route, not past the onset.
• Known source, batch-matched certificate, and keep the packaging and any remaining material.
• Tell clinicians the truth about everything taken — drug screens do not detect these compounds.
• Unresponsive but breathing: recovery position, airway clear, stay with them. Not breathing: emergency services now.
• Naloxone if opioids are possible, while calling for help — not instead of it.

Sources: Castaneto MS 2015 · Tait RJ 2015 · Frinculescu A 2016 · America's Poison Centers (formerly the American Association of Poison Control Centers) 2025* · Huestis MA 2007

What this page is not human data

This is a description of documented presentations and documented emergency thresholds, written so that a person can recognise a situation and act on it in time. It is not a diagnosis, not a treatment protocol, and not advice about any particular person. It does not tell anyone what to administer, in what dose, or instead of what. Where it names a threshold, the action attached to that threshold is to get professional help, not to manage the event alone. The clinical management of cannabinoid toxicity — sedation choices, seizure management, cardiac and renal monitoring, fluid resuscitation and everything else — belongs to clinicians with the patient in front of them, and the reason this page exists is to shorten the time until that is who is looking after the person.

Sources: Tait RJ 2015 · Castaneto MS 2014